Phase 1 Asthma Trial, Recruiting NCT07660731 Sponsor: Pfizer Condition: Asthma
Back to Asthma

Phase 1 Asthma Trial, Recruiting

NCT07660731
Recruiting Phase 1

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are male, or female and no longer able to have children
  • You are between 18 and 65 years old
  • Your body mass index (BMI) is between 16 and 32, and you weigh more than 50 kilograms (110 pounds)
  • For one specific optional group (Part A, Japanese participants only): you weigh more than 45 kg (100 pounds) and all four of your biological grandparents were born in Japan
  • For Part E only: you have been formally diagnosed by a doctor with asthma for at least 12 months before joining the study, and your BMI is between 16 and 35 with a weight over 50 kilograms (110 pounds)

Who may not be able to join:

  • You have a significant history of serious medical conditions (confirm with trial site)
  • You have a history of HIV, hepatitis B, or hepatitis C, or you test positive for any of these
  • You have had alcohol abuse, binge drinking, or use of illegal drugs or substances in the past 6 months
  • You are currently taking part in, or plan to take part in, another clinical trial involving an experimental drug or vaccine at the same time
  • You have had a parasitic infection that needed treatment within the last 28 days
  • You have tested positive for tuberculosis
  • For Part C only: you have a history of conditions that affect your ability to taste
  • For Part D only: you have a history of irregular bowel movements
  • For Part E only: you have a lung condition other than asthma
  • For Part E only: you have had a worsening of your asthma symptoms within the past 3 months
  • For Part F only: you have a history of certain eye, breathing, nerve, or muscle conditions, or have had a bad reaction to certain sedative medications (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 20 July 2026
Phase 1: approximately ~10% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Pfizer CT.gov Call Center, Pfizer

Phone: 1-800-718-1021

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 1
Sponsor
Registry
ClinicalTrials.gov
Start date
17 June 2026
Est. completion
18 June 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Number of Participants with Treatment Emergent Adverse Events (TEAEs); Number of Participants with Serious Adverse Events (SAEs); Number of Participants With Clinically Significant Change From Baseline in Laboratory Abnormalities; Number of Participants With Clinically Significant Change From Baseline in Vital Signs; Number of Participants With Clinically Significant Change From Baseline in Electrocardiogram (ECG) Findings; Area under the curve from time zero to extrapolated infinite time (AUCinf) if data permit, otherwise (AUClast) in the fasted state; Maximum observed plasma concentration (C...

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 20 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov